Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FHL-501
- Development stage
- Preclinical
- Lead developer
- Forest Hills Business Association
- Modality
- Peptides
01
Overview
FHL-501 is a **preclinical peptide therapeutic** being developed by Forest Hills Business Association for neurodegenerative and acute neurologic indications including Alzheimer's Disease, Parkinson's Disease, Stroke, and Lewy Body Dementia. Available company and contextual information indicates that FHL-501 is designed to inhibit the **NF-kappaB inflammatory pathway**, with reported preclinical effects including reduction of brain inflammation, protection of dopaminergic neurons, and promotion of lysosomal biogenesis-mediated clearance of pathogenic molecules. Molecular target-level disclosure remains limited, but the program is positioned as a neuroprotective and anti-inflammatory peptide candidate within the company's neurodegeneration pipeline.
Beyond the preview
Go deeper on FHL-501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FHL-501.